ReviewCNS drugs2026
Cerebral Aspergillosis: Diagnostic Challenges, Therapeutic Strategies, and Future Research.
Review in CNS drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Cerebral Aspergillosis in a Patient on Ibrutinib: A Case of Diagnostic Ambiguity and Multidisciplinary Care.Cureus · 2026Article
- Clinical characteristics, diagnosis, and management of central nervous system aspergillosis in children: a single-center experience.BMC infectious diseases · 2026Article
- Aspergillosis: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment.Journal of fungi (Basel, Switzerland) · 2026Review
- Invasive mould infections of the central nervous system in the Indian population: a cohort study (2004-2025).The Lancet regional health. Southeast Asia · 2026Article
- Angioinvasion severity and admission GCS predict outcomes in invasive central nervous system fungal infections.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral aspergillosis is a well-recognized and particularly severe manifestation of invasive aspergillosis, primarily affecting immunocompromised individuals. The condition is associated with high morbidity and mortality, largely due to diagnostic challenges and limited treatment options. This review examines the epidemiology, risk factors, and diagnostic issues before focusing on drug treatment, including the pharmacokinetics and pharmacodynamics of antifungal agents in the central nervous system. Resistance to current antifungal therapies is also discussed, along with future research directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.